Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients

NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis

(2014) J. A. Berzofsky et al.   JOURNAL OF IMMUNOLOGY

Immune characterization of an individual with an exceptionally high natural killer T cell frequency and her immediate family

(2009) A. C. Chan et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Natural Killer T Cells and Autoimmune Disease

(2009) Lan Wu et al.   CURRENT MOLECULAR MEDICINE

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

(2008) L. Ades et al.   BLOOD

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

(2008) Christine Galustian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy

(2008) W. Song et al.   CLINICAL CANCER RESEARCH

CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system

(2008) Jennifer L Matsuda et al.   CURRENT OPINION IN IMMUNOLOGY

Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis

(2008) M. Cazzola   HAEMATOLOGICA

Myelodysplastic syndromes: biology and treatment

(2008) M. Jädersten et al.   JOURNAL OF INTERNAL MEDICINE

T Cells and NKT Cells in the Pathogenesis of Asthma

(2007) Everett H. Meyer et al.   Annual Review of Medicine